JP5732664B2 - 子宮内膜受容性の診断方法 - Google Patents
子宮内膜受容性の診断方法 Download PDFInfo
- Publication number
- JP5732664B2 JP5732664B2 JP2012549374A JP2012549374A JP5732664B2 JP 5732664 B2 JP5732664 B2 JP 5732664B2 JP 2012549374 A JP2012549374 A JP 2012549374A JP 2012549374 A JP2012549374 A JP 2012549374A JP 5732664 B2 JP5732664 B2 JP 5732664B2
- Authority
- JP
- Japan
- Prior art keywords
- endometrial
- female
- pgf2α
- pge2
- mammalian
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000002357 endometrial effect Effects 0.000 title claims description 190
- 238000002405 diagnostic procedure Methods 0.000 title description 2
- 238000000034 method Methods 0.000 claims description 126
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 claims description 119
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 114
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 105
- 229960002986 dinoprostone Drugs 0.000 claims description 104
- 239000012530 fluid Substances 0.000 claims description 95
- 239000000523 sample Substances 0.000 claims description 80
- 150000003180 prostaglandins Chemical class 0.000 claims description 52
- 230000032692 embryo implantation Effects 0.000 claims description 44
- 241000124008 Mammalia Species 0.000 claims description 24
- 238000004811 liquid chromatography Methods 0.000 claims description 21
- 239000013074 reference sample Substances 0.000 claims description 15
- PXGPLTODNUVGFL-UHFFFAOYSA-N prostaglandin F2alpha Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CC=CCCCC(O)=O PXGPLTODNUVGFL-UHFFFAOYSA-N 0.000 claims description 10
- 238000004885 tandem mass spectrometry Methods 0.000 claims description 10
- 230000001965 increasing effect Effects 0.000 claims description 7
- 208000000509 infertility Diseases 0.000 claims description 3
- 230000036512 infertility Effects 0.000 claims description 3
- 231100000535 infertility Toxicity 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 2
- 208000007984 Female Infertility Diseases 0.000 claims 1
- 206010021928 Infertility female Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 description 71
- 230000027758 ovulation cycle Effects 0.000 description 51
- 238000002513 implantation Methods 0.000 description 38
- 210000004696 endometrium Anatomy 0.000 description 31
- 210000001161 mammalian embryo Anatomy 0.000 description 29
- 238000004949 mass spectrometry Methods 0.000 description 29
- 150000001875 compounds Chemical class 0.000 description 28
- 239000000090 biomarker Substances 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 18
- 239000012071 phase Substances 0.000 description 18
- 230000035935 pregnancy Effects 0.000 description 18
- 150000003169 prostaglandin F2α derivatives Chemical class 0.000 description 18
- 230000028327 secretion Effects 0.000 description 18
- 230000004720 fertilization Effects 0.000 description 16
- 230000035800 maturation Effects 0.000 description 16
- 238000000338 in vitro Methods 0.000 description 15
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 15
- 210000004291 uterus Anatomy 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 102000009151 Luteinizing Hormone Human genes 0.000 description 11
- 108010073521 Luteinizing Hormone Proteins 0.000 description 11
- 229940040129 luteinizing hormone Drugs 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 238000012546 transfer Methods 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 238000012544 monitoring process Methods 0.000 description 10
- 230000008569 process Effects 0.000 description 9
- 210000004907 gland Anatomy 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 230000003248 secreting effect Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- DZUXGQBLFALXCR-UHFFFAOYSA-N (+)-(9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CCCCCCC(O)=O DZUXGQBLFALXCR-UHFFFAOYSA-N 0.000 description 7
- 238000001574 biopsy Methods 0.000 description 7
- 239000003433 contraceptive agent Substances 0.000 description 7
- 210000002257 embryonic structure Anatomy 0.000 description 7
- 210000000981 epithelium Anatomy 0.000 description 7
- KQXDGUVSAAQARU-HZJYTTRNSA-N linoleoyl ethanolamide Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)NCCO KQXDGUVSAAQARU-HZJYTTRNSA-N 0.000 description 7
- BOWVQLFMWHZBEF-KTKRTIGZSA-N oleoyl ethanolamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCO BOWVQLFMWHZBEF-KTKRTIGZSA-N 0.000 description 7
- HXYVTAGFYLMHSO-UHFFFAOYSA-N palmitoyl ethanolamide Chemical compound CCCCCCCCCCCCCCCC(=O)NCCO HXYVTAGFYLMHSO-UHFFFAOYSA-N 0.000 description 7
- DZUXGQBLFALXCR-CDIPTNKSSA-N prostaglandin F1alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1CCCCCCC(O)=O DZUXGQBLFALXCR-CDIPTNKSSA-N 0.000 description 7
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 5
- 210000003756 cervix mucus Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000002254 contraceptive effect Effects 0.000 description 5
- 230000035558 fertility Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 4
- 210000003679 cervix uteri Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 238000004445 quantitative analysis Methods 0.000 description 4
- -1 sterol esters Chemical class 0.000 description 4
- FVXDCNFHHUUREB-UHFFFAOYSA-N (7Z,10Z,13Z,16Z)-1-amino-2-hydroxydocosa-7,10,13,16-tetraen-3-one Chemical compound C(CCCC=C/CC=C/CC=C/CC=C/CCCCC)(=O)C(O)CN FVXDCNFHHUUREB-UHFFFAOYSA-N 0.000 description 3
- RCRCTBLIHCHWDZ-DOFZRALJSA-N 2-arachidonoylglycerol Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC(CO)CO RCRCTBLIHCHWDZ-DOFZRALJSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 238000003744 In vitro fertilisation Methods 0.000 description 3
- OTGQIQQTPXJQRG-UHFFFAOYSA-N N-(octadecanoyl)ethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCO OTGQIQQTPXJQRG-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 210000005168 endometrial cell Anatomy 0.000 description 3
- 230000032686 female pregnancy Effects 0.000 description 3
- 230000000762 glandular Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000002705 metabolomic analysis Methods 0.000 description 3
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 230000035752 proliferative phase Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- RCRCTBLIHCHWDZ-UHFFFAOYSA-N 2-Arachidonoyl Glycerol Chemical compound CCCCCC=CCC=CCC=CCC=CCCCC(=O)OC(CO)CO RCRCTBLIHCHWDZ-UHFFFAOYSA-N 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 229940124558 contraceptive agent Drugs 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000005040 ion trap Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000622 liquid--liquid extraction Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003821 menstrual periods Effects 0.000 description 2
- 230000001431 metabolomic effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000002552 multiple reaction monitoring Methods 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- PXGPLTODNUVGFL-NAPLMKITSA-N 8-epi-prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-NAPLMKITSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010061452 Complication of pregnancy Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100029880 Glycodelin Human genes 0.000 description 1
- 101000585553 Homo sapiens Glycodelin Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 239000004015 abortifacient agent Substances 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003375 cannabimimetic effect Effects 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229960001342 dinoprost Drugs 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000012615 high-resolution technique Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940074383 interleukin-11 Drugs 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000002346 layers by function Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000000938 luteal effect Effects 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000028742 placenta development Effects 0.000 description 1
- 238000001121 post-column derivatisation Methods 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- PXGPLTODNUVGFL-YNNPMVKQSA-N prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-YNNPMVKQSA-N 0.000 description 1
- 238000003498 protein array Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012764 semi-quantitative analysis Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/42—Gynaecological or obstetrical instruments or methods
- A61B17/425—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation
- A61B17/435—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation for embryo or ova transplantation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/367—Infertility, e.g. sperm disorder, ovulatory dysfunction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/104165—Lipid, cholesterol, or triglyceride standard or control
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10382011.4 | 2010-01-21 | ||
| EP10382011A EP2348318A1 (en) | 2010-01-21 | 2010-01-21 | Diagnostic method for endometrial receptivity |
| PCT/EP2011/050867 WO2011089240A1 (en) | 2010-01-21 | 2011-01-21 | Diagnostic method for endometrial receptivity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013518244A JP2013518244A (ja) | 2013-05-20 |
| JP2013518244A5 JP2013518244A5 (enExample) | 2014-03-06 |
| JP5732664B2 true JP5732664B2 (ja) | 2015-06-10 |
Family
ID=42200845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012549374A Expired - Fee Related JP5732664B2 (ja) | 2010-01-21 | 2011-01-21 | 子宮内膜受容性の診断方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20130144114A1 (enExample) |
| EP (2) | EP2348318A1 (enExample) |
| JP (1) | JP5732664B2 (enExample) |
| CN (1) | CN102792166B (enExample) |
| BR (1) | BR112012018289A2 (enExample) |
| CA (1) | CA2787582A1 (enExample) |
| DK (1) | DK2526425T3 (enExample) |
| ES (1) | ES2485847T3 (enExample) |
| PL (1) | PL2526425T3 (enExample) |
| WO (1) | WO2011089240A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010010201A1 (es) | 2008-07-22 | 2010-01-28 | Equipo Ivi Investigacion Sl | Perfil de expresion genetica como marcador de la receptividad endometrial |
| US9107696B2 (en) * | 2008-08-06 | 2015-08-18 | Emory University | Method of embryo transfer that eliminates transferred air while hormonally inducing implantation and apparatus |
| ES2972747T3 (es) | 2009-08-22 | 2024-06-14 | Ares Trading Sa | Obtención de imágenes y evaluación de embriones, ovocitos y células madre |
| WO2012047678A2 (en) | 2010-09-27 | 2012-04-12 | Auxogyn, Inc. | Apparatus, method, and system for the automated imaging and evaluation of embryos, oocytes, and stem cells |
| CA2827945C (en) | 2011-02-23 | 2021-10-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of detecting aneuploidy in human embryos |
| WO2013135836A1 (en) * | 2012-03-14 | 2013-09-19 | Centre Hospitalier Universitaire Pontchaillou | Itih5 as a diagnostic marker of uterine development and functional defects |
| EP2687851A1 (en) | 2012-07-20 | 2014-01-22 | Matricelab Innove | Method for increasing implantation success in assisted fertilization |
| WO2014121200A1 (en) | 2013-02-01 | 2014-08-07 | Auxogyn, Inc. | Abnormal syngamy phenotypes observed with time lapse imaging for early identification of embryos with lower developmental potential |
| RU2562559C1 (ru) * | 2014-05-27 | 2015-09-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт акушерства и гинекологии им. Д.О. Отта" Северо-Западного отделения Российской академии медицинских наук | Способ прогнозирования рецептивности эндометрия в циклах экстракорпорального оплодотворения |
| ES2736117T3 (es) | 2014-06-17 | 2019-12-26 | Igenomix S L | Tratamiento de células madre en patologías endometriales |
| CN105486799B (zh) * | 2016-01-25 | 2017-12-01 | 中国药科大学 | 用于诊断急性冠脉综合征的代谢标志物 |
| CN105445408B (zh) * | 2016-01-25 | 2018-06-12 | 齐炼文 | 诊断区分冠状动脉粥样硬化和稳定型心绞痛的代谢标志物 |
| EP3545107A2 (en) * | 2016-11-22 | 2019-10-02 | Quantbio Kft | Determination of the receptive status of the endometrium |
| RU2651762C1 (ru) * | 2017-06-14 | 2018-04-23 | Федеральное государственное бюджетное учреждение "Уральский научно-исследовательский институт охраны материнства и младенчества" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ ОММ" Минздрава России) | Способ оценки рецептивности эндометрия в период "имплантационного окна" |
| EP3569718A1 (en) * | 2018-05-16 | 2019-11-20 | Integrated Genetic Lab Services SLU | Kit and method for determining the receptivity status of an endometrium |
| AU2020212604A1 (en) * | 2019-01-25 | 2021-07-22 | Fertility Lab Sciences, Llc | Uterine endometrial fluid for prediction of success in fertility treatment |
| WO2020160612A1 (en) * | 2019-02-05 | 2020-08-13 | The University Of Sydney | Uterine receptivity |
| EP3779455A1 (en) * | 2019-08-14 | 2021-02-17 | Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE | Lipid signatures for determining the outcome of embryo implantation during in vitro fertilization |
| CN111505311A (zh) * | 2020-04-30 | 2020-08-07 | 深圳市锦欣医疗科技创新中心有限公司 | 一组胚胎反复种植失败的生物标志物、其筛选方法及应用 |
| CN111505312A (zh) * | 2020-04-30 | 2020-08-07 | 深圳市锦欣医疗科技创新中心有限公司 | 一组子宫内膜受容性的生物标志物、其筛选方法及应用 |
| TWI791347B (zh) * | 2020-12-11 | 2023-02-01 | 酷氏基因生物科技股份有限公司 | 一種用於評估胚胎植入成功率的預測方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05501541A (ja) * | 1989-05-05 | 1993-03-25 | ノーザン シドニー エリア ヘルス サーヴィス | 繁殖力増強 |
| GB0201284D0 (en) | 2002-01-21 | 2002-03-06 | Isis Innovation | Screening methods for contraceptive and fertility agents |
| US20040005612A1 (en) * | 2002-05-14 | 2004-01-08 | Giudice Linda C. | Endometrial genes in endometrial disorders |
| DE10236405A1 (de) * | 2002-08-02 | 2004-02-19 | Schering Ag | Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie |
| ES2273061T3 (es) * | 2002-08-02 | 2007-05-01 | Schering Aktiengesellschaft | Agentes moduladores de receptores de progesterona con actividad antigonadotropa elevada para el control de fertilidad femenina y para la terapia por reemplazo hormonal. |
| CN1863905A (zh) * | 2003-09-08 | 2006-11-15 | 得克萨斯系统大学董事会 | 通过用前列腺素或前列腺素类似物补充培养基加强体外胚发育的方法以及组合物 |
| AU2005249504A1 (en) * | 2004-05-28 | 2005-12-15 | Laboratoires Serono Sa | Use of IL-17 in the treatment of fertility-related disorders |
| JP2007278750A (ja) * | 2006-04-04 | 2007-10-25 | Ono Pharmaceut Co Ltd | プロスタグランジン類及びその類縁体の定量方法 |
-
2010
- 2010-01-21 EP EP10382011A patent/EP2348318A1/en not_active Withdrawn
-
2011
- 2011-01-21 US US13/574,291 patent/US20130144114A1/en not_active Abandoned
- 2011-01-21 EP EP11700679.1A patent/EP2526425B1/en not_active Not-in-force
- 2011-01-21 JP JP2012549374A patent/JP5732664B2/ja not_active Expired - Fee Related
- 2011-01-21 WO PCT/EP2011/050867 patent/WO2011089240A1/en not_active Ceased
- 2011-01-21 DK DK11700679.1T patent/DK2526425T3/da active
- 2011-01-21 CA CA2787582A patent/CA2787582A1/en not_active Abandoned
- 2011-01-21 CN CN201180010375.0A patent/CN102792166B/zh not_active Expired - Fee Related
- 2011-01-21 ES ES11700679.1T patent/ES2485847T3/es active Active
- 2011-01-21 PL PL11700679T patent/PL2526425T3/pl unknown
- 2011-01-21 BR BR112012018289-7A patent/BR112012018289A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013518244A (ja) | 2013-05-20 |
| US20130144114A1 (en) | 2013-06-06 |
| EP2348318A1 (en) | 2011-07-27 |
| BR112012018289A2 (pt) | 2021-04-20 |
| PL2526425T3 (pl) | 2014-11-28 |
| HK1177636A1 (zh) | 2013-08-23 |
| ES2485847T3 (es) | 2014-08-14 |
| DK2526425T3 (da) | 2014-08-04 |
| CA2787582A1 (en) | 2011-07-28 |
| WO2011089240A1 (en) | 2011-07-28 |
| EP2526425B1 (en) | 2014-04-30 |
| EP2526425A1 (en) | 2012-11-28 |
| CN102792166A (zh) | 2012-11-21 |
| CN102792166B (zh) | 2015-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5732664B2 (ja) | 子宮内膜受容性の診断方法 | |
| Edgell et al. | Assessing receptivity in the endometrium: the need for a rapid, non-invasive test | |
| Matsui et al. | Liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay for simultaneous measurement of salivary testosterone and cortisol in healthy men for utilization in the diagnosis of late-onset hypogonadism in males | |
| CN103415769B (zh) | 用于妊娠性高血压疾病的生物标志物和参数 | |
| ES2211871T3 (es) | Procedimiento para la deteccion de un parto prematuro. | |
| CA2859295A1 (en) | Biomarkers and parameters for preeclampsia | |
| Koh et al. | Proteome profiling of exosomes derived from plasma of heifers with divergent genetic merit for fertility | |
| KR101467372B1 (ko) | 타액을 이용한 생리활성 진단 방법 | |
| Mikucka-Niczyporuk et al. | Role of sphingolipids in the pathogenesis of intrahepatic cholestasis | |
| CN118903215A (zh) | 试剂在制备治疗或改善心力衰竭的药物中的用途及药物筛选方法 | |
| Auray-Blais et al. | Metabolomics and preterm birth: What biomarkers in cervicovaginal secretions are predictive of high-risk pregnant women? | |
| CN113748344A (zh) | 肥胖孕妇先兆子痫风险的检测 | |
| CN117512096A (zh) | 用于预测反复着床失败发生的标志物及其应用 | |
| JP2013531799A (ja) | 妊娠の高血圧障害についてのバイオマーカー | |
| US20140093900A1 (en) | Steroid profile in ovarian follicular fluid for diagnosis, prognosis and determining strategies for treatment | |
| WO2013170369A1 (en) | Early predictive markers of pre-eclampsia | |
| US20220308075A1 (en) | Lipid profiling methods for predicting positive pregnancy outcome | |
| Wang et al. | Hepcidin levels in hyperprolactinemic women monitored by nanopore thin film based assay: correlation with pregnancy-associated hormone prolactin | |
| KR20110068906A (ko) | 타액을 이용한 생리활성 진단 방법 | |
| Zheng et al. | Metabolomics analysis of serum metabolites during endometrial transformation: association with recurrent implantation failure in hormonal replacement therapy-frozen embryo transfers cycles | |
| HK1177636B (en) | Diagnostic method for endometrial receptivity | |
| JP2000513208A (ja) | Ｉｖｆの成果についての予測アッセイ | |
| Albayrak et al. | A simple HPLC method for the determination of plasma progesterone levels in the third trimester of human pregnancy | |
| Pařízek et al. | The Endocannabinoid System-The Prediction of Spontaneous Preterm Birth in High-Risk Women: Protocol of a Study | |
| CN110785664A (zh) | 流产中的特征性代谢物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140115 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140115 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140724 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140902 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141201 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150120 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150218 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20150320 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150320 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150320 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5732664 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |